These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29534618)

  • 1. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
    Maakaron JE; Rogosheske J; Long M; Bachanova V; Mims AS
    J Clin Pharmacol; 2021 Jan; 61(1):7-17. PubMed ID: 32875599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
    Kung Sutherland MS; Walter RB; Jeffrey SC; Burke PJ; Yu C; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; Zeng W; Harrington KH; Klussman K; Westendorf L; Meyer D; Bernstein ID; Senter PD; Benjamin DR; Drachman JG; McEarchern JA
    Blood; 2013 Aug; 122(8):1455-63. PubMed ID: 23770776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CD33 as therapeutic target in acute myeloid leukemia.
    Walter RB
    Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
    Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
    Laszlo GS; Estey EH; Walter RB
    Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
    Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
    Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
    Stein EM; Walter RB; Erba HP; Fathi AT; Advani AS; Lancet JE; Ravandi F; Kovacsovics T; DeAngelo DJ; Bixby D; Faderl S; Jillella AP; Ho PA; O'Meara MM; Zhao B; Biddle-Snead C; Stein AS
    Blood; 2018 Jan; 131(4):387-396. PubMed ID: 29196412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
    Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
    J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
    Rashidi A; Walter RB
    Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
    Morsink LM; Walter RB
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
    Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
    Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Godwin CD; Laszlo GS; Fiorenza S; Garling EE; Phi TD; Bates OM; Correnti CE; Hoffstrom BG; Lunn MC; Humbert O; Kiem HP; Turtle CJ; Walter RB
    Leukemia; 2021 Sep; 35(9):2496-2507. PubMed ID: 33589747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.